Viridian Therapeutics, Inc. (0K1R.L)
- Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., April 04, 2024--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 102,000 shares of the company’s common stock to th
- Business Wire
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
WALTHAM, Mass., March 05, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11 at 2:00 p.m. ET.
- Simply Wall St.
Viridian Therapeutics Full Year 2023 Earnings: Misses Expectations
Viridian Therapeutics ( NASDAQ:VRDN ) Full Year 2023 Results Key Financial Results Net loss: US$237.7m (loss widened by...
